-
Mashup Score: 23
PARP inhibitors can upregulate PD-L1 expression and promote immune-mediated responses, and may improve efficacy of first-line anti‒PD-1‒based therapies in patients with metastatic squamous NSCLC.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Lung Cancer in Argentina - 12 day(s) ago
Argentina, the southernmost country in Latin America (LATAM), spans over 1 million square miles with a population of 46 million as of 2022, marking a 15.3% increase since 20101 (Fig. 1). With 18% of its population aged over 65 and 92% residing in urban areas, Argentina presents a diverse landscape both geographically and demographically. It is divided into 24 departments or provinces, including the Autonomous City of Buenos Aires. Almost 70% of the population lives in the richest six central provinces.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Explore Argentina's past & present experience w/detecting & treating thoracic cancers in its current population. To learn more about demographics, tobacco control, & treatment despite the different healthcare options, click here: https://t.co/ehBVsi7v8y #LCSM https://t.co/94xIEVdCFn
-
-
Mashup Score: 70Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study - 12 day(s) ago
Small-cell lung cancer (SCLC) has limited second-line treatment options after chemotherapy. We assessed the efficacy and safety of lurbinectedin combined with pembrolizumab in relapsed SCLC patients who had not received prior immunotherapy, aiming to prevent early progression and achieve sustained responses.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Ph I/II LUPER trial Lurbinectedin+pembrolizumab in relapsed SCLC @JTOonline - 28pts (ph II) - plt-resistant: mPFS 4.6m, mOS 10.5m - plt-sensitive: mPFS 8m, mOS 15.7m - g3+ TRAEs 71.4% Congrats @Tony_Calles on this investigator-led effort! @OncoAlert #LCSM https://t.co/cfgmSfPz9X
-
-
Mashup Score: 146The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population - 13 day(s) ago
While osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, as the first-line therapy for metastatic non-small cell lung cancer (NSCLC) has shown significant survival benefits, concerns have arisen regarding its potential cardiotoxicity, particularly in real-world clinical settings. We aimed to investigate the incidence, risk factors, and reversibility of osimertinib-related cardiotoxicity.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Cardiotoxicity of osimertinib in real world population with #EGFR NSCLC @JTOonline. In 1126 pts, incidence of osimertinib-related cardiac dysfunction was 4.7% (3.4% required some intervention). Recovery rate was 82.4% (similar if discontinued or not). https://t.co/t41aDXmvmN
-
-
Mashup Score: 139Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study - 13 day(s) ago
Small-cell lung cancer (SCLC) has limited second-line treatment options after chemotherapy. We assessed the efficacy and safety of lurbinectedin combined with pembrolizumab in relapsed SCLC patients who had not received prior immunotherapy, aiming to prevent early progression and achieve sustained responses.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Results from phase I/II LUPER study of lurbinectedin + pembrolizumab in #SCLC @JTOonline. RR 46.4% including 3 CR with DOR 7.8m, PFS 4.6m, OS 10.5m. In platinum sensitive, PFS 8m, OS 15.7m. Combination data relevant in light of forthcoming IMforte data. https://t.co/1WPfyBvqd0
-
-
Mashup Score: 25Denial of Access to CT Screening for Nonsmokers Is Unjust - 14 day(s) ago
In their recent article, Silvestri et al.1 analyze results of computed tomography (CT) lung cancer screening (LCS) in Asia and argue against expansion of LCS to include nonsmokers (NS), based primarily on their repeated and emphatic assertion that most CT-detected LC in NS are overdiagnosed (OD). To support their hypothesis, they emphasize detection of many LC in early stage without reduction in advanced-stage LC or deaths.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
"Denial of Access to CT Screening for Nonsmokers Is Unjust". https://t.co/e9jCNENV7l https://t.co/YmpDnma1ob
-
-
Mashup Score: 41Risk factors for locoregional relapse after segmentectomy: Supplementary analysis of the JCOG0802/WJOG4607L trial - 14 day(s) ago
The JCOG0802/WJOG4607L trial revealed superior overall survival in segmentectomy to lobectomy for small-peripheral non-small-cell lung cancer. However, locoregional relapse (LR) is a major issue for segmentectomy. An ad hoc supplementary analysis aimed to determine the risk factors for LR and the degree of advantages of segmentectomy based on primary tumor sites.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Analysis of locoregional relapse after segmentectomy in JCOG0802 @JTOonline. Multivariable analysis associates pure-solid on thin-section CT (OR 3.23), margin < tumor size (OR 2.68), & male sex (OR 2.09) with LR. Trend in left lingular segment site. https://t.co/ENfJmTT0Pm
-
-
Mashup Score: 54
Ivonescimab is a humanized IgG1 bispecific anti-PD-1/VEGF antibody. This study aimed to evaluate the safety and tolerance of ivonescimab combined with etoposide and carboplatin as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC) and explore the primary efficacy of this regimen.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Phase Ib study of ivonescimab (PD-1 VEGF bispecific) with first-line carboplatin + etoposide in #SCLC @JTOonline. In 35 pts, RR 80%, PFS 6.9m, OS 14.5m, G3+ TRAEs in 60% with most frequent being neutropenia (23%). https://t.co/xzevizuy8P
-
-
Mashup Score: 3PP01.52 The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study - 19 day(s) ago
Molecular testing has identified an increasing number of NSCLC associated genes, but their exact roles are poorly understood. The development of immune checkpoint inhibitors (ICIs) has improved NSCLC outcomes, but there are still limited predictive biomarkers for ICI response. We hypothesize that altered RNA expression impacts tumor immune infiltration in NSCLC and that these relationships can help guide biomarker development.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
PP01.52 The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study [Jul 2024] Faith et al. @RyanNguyenDO @IASLC J Thoracic Oncol https://t.co/REQvz25eS3 #PrecisionMedicine #ImmunoOnc #lcsm
-
-
Mashup Score: 79Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report - 21 day(s) ago
Although hyperlipidemia is a well-known adverse event associated with lorlatinib treatment, lorlatinib-associated hyperglycemia is less common but can be potentially life-threatening. We present the case of a 65-year-old male patient with anaplastic lymphoma kinase–positive lung cancer and preexisting type 2 diabetes mellitus who developed diabetic ketoacidosis (DKA) after switching from alectinib to lorlatinib. After initiating lorlatinib treatment, the patient’s glycemic control deteriorated rapidly, with the glycated hemoglobin levels increasing from 6% to 11.5% within three months.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Case of diabetic ketoacidosis associated with lorlatinib in patient with #ALK NSCLC @JTOonline. Helpful reminder that hyperglycemia can be seen with lorlatinib - important to adjust medications appropriately in event of this AE. https://t.co/BFLWm4WEdJ
-
"In the Keylynk-008 trial, the addition of Olaparib to pembrolizumab following chemoimmunotherapy did not significantly improve PFS in advanced nonsquamous #NSCLC. We did not identify new safety signals in the study". More: https://t.co/sqgNJ3sBFi @hausruck1 @NadalErnest #LCSM https://t.co/dSgIJ0b18C